Finerenone

Clinical Indication

Stage 3 and 4 chronic kidney disease associated with diabetes

Comments

For treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults in line with NICE TA877. Use in line with the CKD Pathway.

Date of classification

May 2023

Green

Medicines which could be started in any health care setting and do not require oversight by a specialist and which primary care would have full responsibility for prescribing and monitoring.